Immune Checkpoints in Cancers: From Signaling to the Clinic

Simple Summary Immune checkpoint therapies are treatments used to fight cancers by reactivating a patient's own immune system. Melanoma was the first cancer to benefit from these treatments. Despite a clear benefit for patients and the existence of long responders, most patients fail to respond or develop resistance to these treatments. In this review, we discuss immune checkpoint signaling in the different immune cells with their biological consequences and summarize new immune checkpoint therapies that are under investigation in clinical trials or in development to bypass resistances and to improve the outcome of these therapies. The immune system is known to help fight cancers. Ten years ago, the first immune checkpoint inhibitor targeting CTLA4 was approved by the FDA to treat patients with metastatic melanoma. Since then, immune checkpoint therapies have revolutionized the field of oncology and the treatment of cancer patients. Numerous immune checkpoint inhibitors have been developed and tested, alone or in combination with other treatments, in melanoma and other cancers, with overall clear benefits to patient outcomes. However, many patients fail to respond or develop resistance to these treatments. It is therefore essential to decipher the mechanisms of action of immune checkpoints and to understand how immune cells are affected by signaling to be able to understand and overcome resistance. In this review, we discuss the signaling and effects of each immune checkpoint on different immune cells and their biological and clinical relevance. Restoring the functionality of T cells and their coordination with other immune cells is necessary to overcome resistance and help design new clinical immunotherapy strategies. In this respect, NK cells have recently been implicated in the resistance to anti-PD1 evoked by a protein secreted by melanoma, ITGBL1. The complexity of this network will have to be considered to improve the efficiency of future immunotherapies and may lead to the discovery of new immune checkpoints.

Automated summary

Immune checkpoint therapies have revolutionized cancer treatment by reactivating the patient's immune system. Despite clear benefits observed in patients, many still fail to respond or develop resistance to these treatments. Understanding the mechanisms of immune checkpoints is essential for overcoming resistance and improving clinical outcomes.